Gilead CEO Daniel O'Day (Credit: Georgios Kefalas/AP)
November 7, 2019 07:21 AM ESTUpdated 10:36 AM
Pharma
FDA+

HHS is tak­ing Gilead to court, seek­ing dam­ages for in­fring­ing gov­ern­ment HIV patents

Natalie Grover

Reporter

Gilead ear­li­er this year fired an open­ing sal­vo by march­ing to the US Patent and Trade­mark Of­fice and re­quest­ing a re­view of the

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis ups in­come guid­ance, ini­ti­ates $10B share buy­back

Sarep­ta adds black box warn­ing to its Duchenne treat­ment, cuts 500 work­ers

Cure­Vac CEO on BioN­Tech deal: Come to­geth­er 'rather than fight­ing each oth­er in court'

Mas­sive pro­teomics study re­veals new clues about Alzheimer’s and rekin­dles old ones

OpenEv­i­dence raised $210M in GV's 'most com­pet­i­tive' deal

BioN­Tech's strat­e­gy chief, who led deals to re­shape com­pa­ny, will leave in Sep­tem­ber

A service from the Financial Times